These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9628225)

  • 41. Long terminal repeat sequences from virulent and attenuated equine infectious anemia virus demonstrate distinct promoter activities.
    Zhou T; Yuan XF; Hou SH; Tu YB; Peng JM; Wen JX; Qiu HJ; Wu DL; Chen HC; Wang XJ; Tong GZ
    Virus Res; 2007 Sep; 128(1-2):58-64. PubMed ID: 17499380
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Differential effects of virulent and avirulent equine infectious anemia virus on macrophage cytokine expression.
    Lim WS; Payne SL; Edwards JF; Kim I; Ball JM
    Virology; 2005 Feb; 332(1):295-306. PubMed ID: 15661161
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Influence of long terminal repeat and env on the virulence phenotype of equine infectious anemia virus.
    Payne SL; Pei XF; Jia B; Fagerness A; Fuller FJ
    J Virol; 2004 Mar; 78(5):2478-85. PubMed ID: 14963146
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Equine infectious anemia virus: development of a simple reproducible method for titrating infectivity of the cell-adapted strain.
    Amborski GF; Jeffers G; Amborski RL; Issel CJ
    Am J Vet Res; 1979 Feb; 40(2):302-4. PubMed ID: 223479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Regulation of equine infectious anemia virus expression.
    Maury W
    J Biomed Sci; 1998; 5(1):11-23. PubMed ID: 9570509
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Decreased infectivity of a neutralization-resistant equine infectious anemia virus variant can be overcome by efficient cell-to-cell spread.
    Wu W; Blythe DC; Loyd H; Mealey RH; Tallmadge RL; Dorman KS; Carpenter S
    J Virol; 2011 Oct; 85(19):10421-4. PubMed ID: 21752904
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro host range of equine infectious anemia virus.
    Benton CV; Brown BL; Harshman JS; Gilden RV
    Intervirology; 1981; 16(4):225-32. PubMed ID: 6177659
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Equine infectious anemia virus envelope evolution in vivo during persistent infection progressively increases resistance to in vitro serum antibody neutralization as a dominant phenotype.
    Howe L; Leroux C; Issel CJ; Montelaro RC
    J Virol; 2002 Nov; 76(21):10588-97. PubMed ID: 12368301
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Long terminal repeat sequences of equine infectious anaemia virus are a major determinant of cell tropism.
    Payne SL; La Celle K; Pei XF; Qi XM; Shao H; Steagall WK; Perry S; Fuller F
    J Gen Virol; 1999 Mar; 80 ( Pt 3)():755-759. PubMed ID: 10092016
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A live attenuated equine infectious anemia virus proviral vaccine with a modified S2 gene provides protection from detectable infection by intravenous virulent virus challenge of experimentally inoculated horses.
    Li F; Craigo JK; Howe L; Steckbeck JD; Cook S; Issel C; Montelaro RC
    J Virol; 2003 Jul; 77(13):7244-53. PubMed ID: 12805423
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characterization of Equine Infectious Anemia Virus Long Terminal Repeat Quasispecies
    Wang XF; Liu Q; Wang YH; Wang S; Chen J; Lin YZ; Ma J; Zhou JH; Wang X
    J Virol; 2018 Apr; 92(8):. PubMed ID: 29386282
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of equine infectious anemia virus disease transmission through in vitro embryo production using somatic cell nuclear transfer.
    Gregg K; Polejaeva I
    Theriogenology; 2009 Aug; 72(3):289-99. PubMed ID: 19482352
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Free-virus and cell-to-cell transmission in models of equine infectious anemia virus infection.
    Allen LJ; Schwartz EJ
    Math Biosci; 2015 Dec; 270(Pt B):237-48. PubMed ID: 25865935
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Incorporation of uracil into viral DNA correlates with reduced replication of EIAV in macrophages.
    Steagall WK; Robek MD; Perry ST; Fuller FJ; Payne SL
    Virology; 1995 Jul; 210(2):302-13. PubMed ID: 7542416
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Equine infectious anemia virus resists the antiretroviral activity of equine APOBEC3 proteins through a packaging-independent mechanism.
    Bogerd HP; Tallmadge RL; Oaks JL; Carpenter S; Cullen BR
    J Virol; 2008 Dec; 82(23):11889-901. PubMed ID: 18818324
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Equine Infectious Anemia Virus (EIAV): what has HIV's country cousin got to tell us?
    Leroux C; Cadoré JL; Montelaro RC
    Vet Res; 2004; 35(4):485-512. PubMed ID: 15236678
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Control of equine infectious anemia virus is not dependent on ADCC mediating antibodies.
    Tschetter JR; Byrne KM; Perryman LE; McGuire TC
    Virology; 1997 Apr; 230(2):275-80. PubMed ID: 9143283
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Equine infectious anemia virus entry occurs through clathrin-mediated endocytosis.
    Brindley MA; Maury W
    J Virol; 2008 Feb; 82(4):1628-37. PubMed ID: 18057237
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discerning an effective balance between equine infectious anemia virus attenuation and vaccine efficacy.
    Craigo JK; Li F; Steckbeck JD; Durkin S; Howe L; Cook SJ; Issel C; Montelaro RC
    J Virol; 2005 Mar; 79(5):2666-77. PubMed ID: 15708986
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Construction and in vitro evaluation of an infectious clone of the equine infectious anemia virus vaccine strain EIAV(FDDV) with four reverse-mutated vaccine-specific sites in the S2 gene].
    Gao X; Jiang CG; Han XE; Zhao LP; Shen RX; Xiang WH; Zhou JH
    Bing Du Xue Bao; 2009 Jul; 25(4):309-15. PubMed ID: 19769166
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.